Vestibular Infant Screening - Rehabilitation
ConditionVestibular Disorder
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3-17
SponsorUniversity Hospital, Ghent
About this trial
The goal of this clinical trial is to investigate the short-term effect of a structured, combined postural control and gaze stabilisation protocol (VIS-REHAB protocol) in a group of vestibular-impaired children of different age categories (3-17 years). The main questions it aims to answer are:
* What is the short-term effect of the VIS-REHAB protocol? * What are the most important factors that may influence the effect of and outcome after application of the VIS-REHAB protocol?
The participant will undergo both an active rehabilitation program (VIS-REHAB protocol) and a period during which physical therapy is discontinued (CTRL protocol).:
\- VIS-REHAB protocol: Postural control (static and dynamic postural stability exercises), gaze stability exercises (oculomotor function and VOR-exercises) \& general gross motor training with focus on gaze stability and postural control.
Researchers will compare the VIS-REHAB protocol with receiving no therapy (CTRL protocol) to evaluate potential enhancements in postural stability, gaze stability, motor performance and quality of life.
Eligibility criteria
Qualifiers
Patients with identified vestibular dysfunction
With or without concomitant hearing loss and/or cochlear implant (CI)
Disqualifiers
Children incapable to understand simple instructions (due to severe cognitive disorders, impaired language comprehension, etc.)
Severe disorders of other primary sensory input systems for balance function
Severe neuromotor disorders (incapable of independent standing and walking)
Severe muscle tone disorders (e.g. cerebral palsy)
Trial design
Treatments tested in this trial
- VIS-REHAB protocol
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Hospital, Ghent
Lead sponsor
University Ghent
Collaborator
Source ClinicalTrials.gov